Breakthrough for treating XDR-TB and ameliorating TB-IRIS
24 April 2017. Related: Conference reports, Coinfections and complications, TB coinfection.
Conference reports
PrEP in pregnancy does not increase poor birth outcomes
24 April 2017. Related: Conference reports, Pregnancy, HIV prevention and transmission.
HIV cure research and basic science: capsules from CROI 2017
24 April 2017. Related: Conference reports, Cure-related research, Basic science and immunology.
24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle
27 February 2017. Related: Conference reports.
Pharmacokinetics and full phase 2 results for bictegravir, a new integrase inhibitor
27 February 2017. Related: Conference reports, Antiretrovirals, PK and drug interactions.
New NNRTI doravirine is non-inferior to darunavir/r in phase 3 treatment naive study
27 February 2017. Related: Conference reports, Antiretrovirals.
NRTI GS-9131 resurfaces at CROI 2017: in vitro sensitivity to nuke-resistant HIV
27 February 2017. Related: Conference reports, Antiretrovirals.
Dolutegravir exposure increases when fixed dose combination tablets are crushed
27 February 2017. Related: Conference reports, Antiretrovirals, Paediatric care.
Pharmacokinetics, safety and efficacy of dolutegravir in very young children
27 February 2017. Related: Conference reports, Antiretrovirals, Paediatric care.
Efavirenz, tenofovir and emtricitabine associated with fewest adverse birth outcomes in Botswana
27 February 2017. Related: Conference reports, Antiretrovirals, Pregnancy.
Adverse pregnancy outcomes and risk factors in the PROMISE trial
27 February 2017. Related: Conference reports, Antiretrovirals, Pregnancy.
Women on lopinavir/ritonavir-based regimens at conception at higher risk of preterm delivery in UK study
27 February 2017. Related: Conference reports, Antiretrovirals, Pregnancy.
No increase in adverse birth outcomes with maternal TDF/FTC in US study
27 February 2017. Related: Conference reports, Pregnancy.
Dolutegravir monotherapy studies halted due to integrase resistance: dual therapy studies continue
27 February 2017. Related: Conference reports, Treatment strategies.
No evidence of accelerated brain ageing in HIV positive people on effective ART
27 February 2017. Related: Conference reports, Ageing and life expectancy.
Acute infection with wild-type HIV on PrEP with good drug levels
27 February 2017. Related: Conference reports, HIV prevention and transmission.
Fit for purpose: antiretroviral treatment optimisation Feb 2017
27 February 2017. Related: Conference reports, Fit for purpose, Antiretrovirals.
Seattle-lite: pre-conference workshops – watch online
27 February 2017. Related: Conference reports, On the web.
International Congress of Drug Therapy in HIV infection (Glasgow 2016), 23-26 October 2016
29 November 2016. Related: Conference reports.
1000-fold mark-up for drug prices in high-income countries blocks access to HIV, HCV and cancer drugs
29 November 2016. Related: Conference reports, Treatment access.
Once-daily raltegravir formulation matches twice-daily results in age, gender, race and baseline viral load/CD4 subgroup analyses
29 November 2016. Related: Conference reports, Antiretrovirals.
Attachment inhibitor GSK-934/BMS-068: 96-week subgroup analysis in treatment-experienced patients
29 November 2016. Related: Conference reports, Antiretrovirals.
Once-weekly albuvirtide infusion: early results of T-20-like compound
29 November 2016. Related: Conference reports, Antiretrovirals.
Simplifying HIV treatment: dual therapy works but monotherapy with either boosted-PIs or dolutegravir does not
29 November 2016. Related: Conference reports, Treatment strategies.
Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients
29 November 2016. Related: Conference reports, PK and drug interactions, TB coinfection.
Further reports of CNS-related side effects with dolutegravir
29 November 2016. Related: Conference reports, Side effects.
Generic PrEP bought online for UK use is validated by drug testing service
29 November 2016. Related: Conference reports, HIV prevention and transmission.
Immunology and HIV persistence – implications for a cure
29 November 2016. Related: Conference reports, Cure-related research.
Selected webcasts from Glasgow 2016
29 November 2016. Related: Conference reports.
2nd HIV Research for Prevention Conference (HIVR4P) 2016, 17-20 October 2016, Chicago
29 November 2016. Related: Conference reports, HIV prevention and transmission.
A burgeoning PrEP pipeline: dozens of new drugs, formulations and delivery options
29 November 2016. Related: Conference reports, HIV prevention and transmission.
Second case of drug resistant HIV infection in person adherent on PrEP
29 November 2016. Related: Conference reports, HIV prevention and transmission.
TDF/FTC can be used as PrEP by breastfeeding mothers without risk to the baby
29 November 2016. Related: Conference reports, Pregnancy, HIV prevention and transmission.
Potential for EFdA as PrEP to prevent HIV transmission in women and their infants
29 November 2016. Related: Conference reports, HIV prevention and transmission.
Antibody therapy leads to sustained post-treatment SIV control in macaques
29 November 2016. Related: Conference reports, Cure-related research.
18th International Workshop on Comorbidities, 12-13 September, New York, USA
1 October 2016. Related: Conference reports.
Fanconi-like lab abnormalities reported with daily PrEP: shows importance of routine kidney monitoring
1 October 2016. Related: Conference reports, Side effects, HIV prevention and transmission.
Bone loss with PrEP in MSM aged 18-24
1 October 2016. Related: Conference reports, Side effects, HIV prevention and transmission.
Neurological side effects with integrase inhibitors cause low rates of discontinuation in clinical practice
1 October 2016. Related: Conference reports, Side effects.
Atripla three days a week for two years: pilot switch study reports undetectable viral load with better bone, kidneys and sleep
1 October 2016. Related: Conference reports, Treatment strategies.
Raltegravir increases waist circumference more than boosted PIs: greater with use of later ART
1 October 2016. Related: Conference reports, Side effects.
Exercise associated with significantly reduced risk of serious health problems and higher CD4 counts in large multicentre US study
1 October 2016. Related: Conference reports, Research studies.
21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa
1 October 2016. Related: Conference reports.
Four day a week ART: sub-optimal drug levels but few virological failures
1 October 2016. Related: Conference reports, Treatment strategies.
Large disparities in costs of antiretrovirals between low- and middle-income countries
1 October 2016. Related: Conference reports, Antiretrovirals, Treatment access.
High risk of virological failure and loss to follow up postpartum in South Africa
1 October 2016. Related: Conference reports, Pregnancy.
Birth weight and preterm delivery outcomes of vertically vs non-vertically infected HIV positive pregnant women
1 October 2016. Related: Conference reports, Pregnancy.
High death rates among HIV positive women postpartum accessing ARVs
1 October 2016. Related: Conference reports, Antiretrovirals, Pregnancy.
Higher rates of eye complications in HIV positive people on ART
1 October 2016. Related: Conference reports, Antiretrovirals, Coinfections and complications.
Short reports on selected Durban posters
1 October 2016. Related: Conference reports.
Global HIV Clinical Forum: Integrase Inhibitors, 16 July 2016, Durban
1 October 2016. Related: Conference reports.
Raltegravir-based third-line ART in children and adolescents
1 October 2016. Related: Conference reports, Antiretrovirals, Paediatric care.
8th International Workshop on HIV Paediatrics, 15-16 July 2016. Durban, South Africa
1 October 2016. Related: Conference reports.
Raltegravir in HIV-exposed neonates
1 October 2016. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Virological response without routine viral load monitoring in children: results from the ARROW trial
1 October 2016. Related: Conference reports, Paediatric care.
Tenofovir-containing ART reduces bone mineral density in breast feeding women: results from IMPAACT P1084s
1 October 2016. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa
1 August 2016. Related: Conference reports.
AIDS 2016: online access to conference programme
1 August 2016. Related: Conference reports.
ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms
1 August 2016. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
ZERO HIV transmissions in PARTNER study: most widely reported i-Base article
1 August 2016. Related: Conference reports, HIV prevention and transmission.
PrEP studies at AIDS 2016: includes first preclinical data with EFdA
1 August 2016. Related: Conference reports, HIV prevention and transmission.
Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study
1 August 2016. Related: Conference reports, Antiretrovirals.
Once-daily raltegravir at last available: 48 week results from ONCEMRK study
1 August 2016. Related: Conference reports, Antiretrovirals.
Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2
1 August 2016. Related: Conference reports, Antiretrovirals.
Dolutegravir is superior to boosted atazanavir in women in the ARIA study
1 August 2016. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.